Skip to main content

and
  1. No Access

    Article

    Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer

    Resistance to chemotherapy remains a critical barrier to effective cancer treatment. Although cisplatin is one of the most commonly used chemotherapeutic agents in the treatment of non-small cell lung cancer (...

    In-Kyu Kim, Justine N. McCutcheon, Guanhua Rao, Stephen V. Liu, Yves Pommier in Oncogene (2019)